Microarray analyses in bladder cancer cells: inhibition of hTERT expression down-regulates EGFR.

PubWeight™: 0.94‹?›

🔗 View Article (PMID 16615118)

Published in Int J Cancer on September 15, 2006

Authors

Kai Kraemer1, Uta Schmidt, Susanne Fuessel, Alexander Herr, Manfred P Wirth, Axel Meye

Author Affiliations

1: Department of Urology, Technical University of Dresden, Dresden, Germany.

Articles by these authors

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int (2006) 3.39

Assessing the accuracy and generalizability of the preoperative and postoperative Karakiewicz nomograms for renal cell carcinoma: results from a multicentre European and US study. BJU Int (2013) 2.08

Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol (2002) 2.02

Second cancers as competing causes of death after radical prostatectomy. J Urol (2009) 2.02

Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin Cancer Res (2003) 1.83

Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial. Prostate (2006) 1.74

Advances in specific immunotherapy for prostate cancer. Eur Urol (2007) 1.70

Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project). Eur Urol (2012) 1.69

Co-expression of survivin and TERT and risk of tumour-related death in patients with soft-tissue sarcoma. Lancet (2002) 1.69

Time to recurrence is a significant predictor of cancer-specific survival after recurrence in patients with recurrent renal cell carcinoma--results from a comprehensive multi-centre database (CORONA/SATURN-Project). BJU Int (2013) 1.60

Prevention and management of complications following radical cystectomy for bladder cancer. Eur Urol (2010) 1.57

Evaluation of dose-volume histograms after prostate seed implantation. 4-year experience. Strahlenther Onkol (2004) 1.44

Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases. Can J Urol (2012) 1.43

Expression of Ki-67 in squamous cell carcinoma of the penis. BJU Int (2005) 1.39

Quantitative multi-gene expression profiling of primary prostate cancer. Prostate (2006) 1.36

Perioperative complications of radical cystectomy in a contemporary series. Eur Urol (2006) 1.35

External validation of a model to predict locoregional failure after radical cystectomy. Cancer (2014) 1.34

Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10K single nucleotide polymorphism mapping array. Neoplasia (2008) 1.32

Comparison of the American Society of Anesthesiologists Physical Status classification with the Charlson score as predictors of survival after radical prostatectomy. Urology (2003) 1.29

Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clin Cancer Res (2005) 1.23

Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 1.21

Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53. Cancer Gene Ther (2004) 1.16

Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJU Int (2010) 1.13

Elevated expression of prostate cancer-associated genes is linked to down-regulation of microRNAs. BMC Cancer (2014) 1.12

Assessment of stem cell/biomaterial combinations for stem cell-based tissue engineering. Biomaterials (2007) 1.12

Elevated expression level of survivin protein in soft-tissue sarcomas is a strong independent predictor of survival. Clin Cancer Res (2003) 1.10

Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast cancer. Eur J Cancer (2005) 1.10

What really matters is rarely measured: outcome of routine care and patient-reported outcomes. Eur Urol (2013) 1.09

Charlson score and competing mortality. Cancer (2014) 1.09

Gene signatures of pulmonary metastases of renal cell carcinoma reflect the disease-free interval and the number of metastases per patient. Int J Cancer (2009) 1.07

Re: Roman Mayr, Matthias May, Thomas Martini, et al. Comorbidity and performance indices as predictors of cancer-independent mortality but not of cancer-specific mortality after radical cystectomy for urothelial carcinoma of the bladder. Eur Urol 2012;62:662-70. Eur Urol (2012) 1.07

Re: Robot-assisted versus open radical prostatectomy: the differential effect of regionalization, procedure volume and operative approach: J. D. Sammon, P. I. Karakiewicz, M. Sun, S. Sukumar, P. Ravi, K. R. Ghani, M. Bianchi, J. O. Peabody, S. F. Shariat, P. Perrotte, J. C. Hu, M. Menon and Q. D. Trinh J Urol 2013; 189: 1289-1294. J Urol (2013) 1.07

Nuclear karyopherin alpha2 expression predicts poor survival in patients with advanced breast cancer irrespective of treatment intensity. Int J Cancer (2008) 1.07

Socio-economic deprivation and cancer survival in Germany. Int J Cancer (2014) 1.07

Comorbidity and mortality after brachytherapy: in regard to Nanda et al. Int J Radiat Oncol Biol Phys (2013) 1.07

Effect of age, tumor risk, and comorbidity in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med (2013) 1.06

Re: Vincenzo Ficarra, Giacomo Novara, Raymond C. Rosen, et al. systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol 2012;62:405-17. Eur Urol (2012) 1.06

Biological activity of a gallic acid-gelatin conjugate. Biomacromolecules (2010) 1.06

Cisplatin, methotrexate and bleomycin for treating advanced penile carcinoma. BJU Int (2006) 1.06

Dendritic cell-based immunotherapy for prostate cancer. Clin Dev Immunol (2010) 1.05

Outcome of surgical treatment of isolated local recurrence after radical nephrectomy for renal cell carcinoma. J Urol (2002) 1.05

siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth. Int J Oncol (2004) 1.03

Multiple tumor marker analyses (PSA, hK2, PSCA, trp-p8) in primary prostate cancers using quantitative RT-PCR. Int J Oncol (2003) 1.01

Which patients are at the highest risk of dying from competing causes ≤ 10 years after radical prostatectomy? BJU Int (2011) 1.00

Isolation and enrichment of urologic tumor cells in blood samples by a semi-automated CD45 depletion autoMACS protocol. Int J Oncol (2002) 0.99

Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients. Int J Cancer (2002) 0.98

Elevated expression of survivin-splice variants predicts a poor outcome for soft-tissue sarcomas patients. Oncogene (2005) 0.98

Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma. PLoS One (2013) 0.97

Transcription profiling of adult and fetal human neuroprogenitors identifies divergent paths to maintain the neuroprogenitor cell state. Stem Cells (2007) 0.97

Impact factor for ranking academic urologic institutions. Eur Urol (2011) 0.96

Contribution of Ca2+ influx to carbachol-induced detrusor contraction is different in human urinary bladder compared to pig and mouse. Eur J Pharmacol (2007) 0.96

CD31, EDNRB and TSPAN7 are promising prognostic markers in clear-cell renal cell carcinoma revealed by genome-wide expression analyses of primary tumors and metastases. Int J Cancer (2012) 0.94

Catecholamines relax detrusor through beta 2-adrenoceptors in mouse and beta 3-adrenoceptors in man. J Pharmacol Exp Ther (2008) 0.94

Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor. Breast Cancer Res Treat (2007) 0.94

Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy. Clin Cancer Res (2007) 0.94

Cholinergic and purinergic responses in isolated human detrusor in relation to age. J Urol (2005) 0.94

Identification of a novel urokinase receptor splice variant and its prognostic relevance in breast cancer. Thromb Haemost (2003) 0.93

Interaction between age and comorbidity as predictors of mortality after radical prostatectomy. J Urol (2008) 0.93

Expression profile of WNT molecules in prostate cancer and its regulation by aminobisphosphonates. J Cell Biochem (2011) 0.93

Detection of circulating tumor cells in peripheral blood of patients with renal cell carcinoma correlates with prognosis. Cancer Epidemiol Biomarkers Prev (2009) 0.93

Superglue in the Urethra: Surgical Treatment. Urol Int (2014) 0.93

Detection of circulating tumor cells from renal carcinoma patients: experiences of a two-center study. Oncol Rep (2005) 0.91

Systematic assessment of complications and outcome of radical cystectomy undertaken with curative intent in patients with comorbidity and over 75 years of age. Urol Int (2013) 0.90

Simultaneous siRNA-mediated knockdown of antiapoptotic BCL2, Bcl-xL, XIAP and survivin in bladder cancer cells. Int J Oncol (2012) 0.90

Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein trp-p8. Prostate (2003) 0.90

Significance of testicular microlithiasis. Urol Int (2005) 0.90

Wavelength-dependent induction of CYP24A1-mRNA after UVB-triggered calcitriol synthesis in cultured human keratinocytes. J Invest Dermatol (2006) 0.89

Pharmacodynamics of propiverine and three of its main metabolites on detrusor contraction. Br J Pharmacol (2005) 0.88

Detection of disseminated tumor cells in peripheral blood of patients with breast cancer: correlation to nodal status and occurrence of metastases. Gynecol Oncol (2004) 0.88